Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
07. November 2023 06:30 ET
|
Verve Therapeutics
U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and...